StockNews.AI
APDN
StockNews.AI
120 days

Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

1. APDN's subsidiary secured U.S.-based input materials for production. 2. This aligns with the BIOSECURE Act and enhances supply chain stability.

2m saved
Insight
Article

FAQ

Why Bullish?

The shift to a U.S.-based supply chain could reduce costs and enhance reliability, similar to past actions from companies like Pfizer which also focused on local resourcing amidst tariff uncertainty.

How important is it?

The article outlines strategic operational changes that directly affect APDN's market position and potential revenues.

Why Long Term?

Establishing a U.S.-based supply chain positions APDN for sustained growth as biopharmaceuticals increasingly favor domestic sourcing, mirroring trends seen in the industry over the past few years.

Related Companies

PFEMRNALLY
- Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain.

Related News